The final day of EADV 2026 explored precision medicine, molecular profiling, atopic dermatitis research, real-world evidence, and emerging approaches to individualized dermatologic care.
|Podcasts|September 11, 2020
Procedure Room Workflow Creating a Space That Enhances the Patient Dermatology Experience
Advertisement
In this episode, Maria Moeller, Marketing Management at Midmark Corporation, discusses the concept of a patient-focused workflow, how the pandemic has impacted procedure workflow, and how dermatologists can cost-effectively adapt procedure rooms to create a safe and efficient patient-centered space.
Advertisement
Related to this article
New EADV 2026 data highlighted real-world outcomes in adults with chronic hand eczema and improvements in itch, pain, and quality of life among adolescents treated with delgocitinib cream.
Day 3 of EADV 2026 featured long-term psoriasis data, advances in hidradenitis suppurativa, evolving approaches to atopic dermatitis, and late-breaking research.
Seven presentations will highlight phase 3 maintenance and induction findings, 3-year phase 2 data, and preclinical research evaluating obefazimod in ulcerative colitis.
Updated phase 2 results from the AMETHYST study showed continued improvements in skin disease activity through 52 weeks, with more than one-quarter of patients achieving clear or almost clear skin.
Christophe Piketty, MD, PhD, discussed 3-year findings from the ARCADIA long-term extension study and the implications of targeting IL-31 in atopic dermatitis.
In TRANQUILLO 2, 21.86% of patients taking ritlecitinib 100 mg achieved F-VASI75 at week 52 vs 2.40% with placebo, according to data presented at EADV 2026.
At 2 years, 70% of patients on oral icotrokinra for scalp, genital, or hand/foot psoriasis had clear or almost clear skin, with no new safety signals.
Advertisement
Advertisement
Trending on Dermatology Times
1
Delgocitinib Shows Real-World Effectiveness and Improved Quality of Life in Chronic Hand Eczema
2
Obefazimod Data Across Phase 3 and Long-Term Studies to Be Presented at UEG Week 2026
3
EADV 2026 Day 3: Long-Term Psoriasis Data and Emerging Therapeutic Targets Take Focus
4
EADV 2026 Day 2: Long-Term AD Data, GLP-1 Nail Findings, and Emerging Treatments Take Center Stage
5